Stock NEPH NEPHROS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Nephros, Inc.

Equities

NEPH

US6406714005

Delayed Nasdaq
Other stock markets
 10:03:49 2024-04-29 EDT 		5-day change 1st Jan Change
2.22 USD +1.37% Intraday chart for Nephros, Inc. +6.22% -35.84%
03-07 Transcript : Nephros, Inc., Q4 2023 Earnings Call, Mar 07, 2024
03-07 Nephros, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Nephros, Inc.

Price target over the last 5 years

History of analyst recommendation changes

2281a.5AwxmQmfJjJsxjPPkGsihbY7LZAfBtiLOTXyan7xIfw.jlkGoWXLEXtcgmmQ_ykR09MDbsoyPpHECnrHIzSrW5u0aX3WVvhhcQbrXA~0fa0b6f4dc16dac7189cc1fbacf005f4

Analyst Recommendations on Nephros, Inc.

B. Riley Securities Lowers Nephros' Price Target to $4.25 from $5.25 Ahead of Q3 Results, Lowers Estimates; Maintains Buy Rating MT
Benchmark Capital Downgrades Nephros to Hold From Speculative Buy MT
B. Riley Lowers Nephros' Price Target to $5.25 from $8 After Lower-than-Expected Q1 Revenue, Keeps Buy Rating MT
B. Riley Lowers Nephros' Price Target to $8 from $11.25, Lowers 2022 Estimates to Align with Management's Guidance; Maintains Buy Rating MT
NEPHROS : B. Riley Starts Nephros at Buy With $12.50 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.19 USD
Average target price
4.75 USD
Spread / Average Target
+116.89%
High Price Target
5 USD
Spread / Highest target
+128.31%
Low Price Target
4.5 USD
Spread / Lowest Target
+105.48%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Nephros, Inc.

B. Riley
Benchmark Capital

Ratings for Nephros, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NEPH Stock
  4. Consensus Nephros, Inc.